オムビタスビル (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "オムビタスビル" in Japanese language version.

refsWebsite

Global rank Japanese rank

low place

low place

447^th place

1,043^rd place

low place

low place

2^nd place

6^th place

doi.org

Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, and Barry Bernstein (2014). “Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin”. N Engl J Med 370: 1594–1603. doi:10.1056/NEJMoa1315722.

fda.gov

“FDA approves Viekira Pak to treat hepatitis C”. Food and Drug Administration (December 19, 2014). 2015年9月2日閲覧。
“FDA approves Technivie for treatment of chronic hepatitis C genotype 4”. Food and Drug Administration (July 24, 2015). 2015年9月2日閲覧。

risfax.co.jp

“厚労省　「ヴィキラックス」「スピオルト」などを承認”. 医薬経済社 (2015年9月29日). 2015年9月29日閲覧。

rxabbvie.com

“VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information”. AbbVie Inc., North Chicago, IL 60064. 30 July 2015閲覧。
“TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information”. AbbVie Inc., North Chicago, IL 60064. 28 July 2015閲覧。